FRANKFURT (Reuters) -Novartis on Tuesday issued a more optimistic full-year earnings guidance, citing strong growth of drugs such as Kisqali, Kesimpta and Leqvio during the first quarter.
The Swiss drugmaker said in a statement that it expects 2025 operating income, adjusted for special items, to grow by a “low double-digit” percentage.
It had previously projected “high single to low double-digit” growth, compared with a 22% increase in 2024.
(Reporting by Ludwig Burger, editing by Thomas Seythal)
